ketoconazole has been researched along with Body Weight in 15 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Four patients with disseminated histoplasmosis, two of whom had late relapses after previous therapy with amphotericin B, were treated with ketoconazole 200 to 400 mg daily for 1 year." | 7.66 | Progressive disseminated histoplasmosis; favorable response to ketoconazole. ( Alford, RH; Gregory, DW; Hawkins, SS, 1981) |
| "Four cats given ketoconazole (30 mg/kg of body weight/day) for 30 days developed dry hair coats and weight loss." | 3.67 | Effect of long-term administration of ketoconazole in cats. ( Fooshee, SK; Howard, VC; Nachreiner, RF; Willard, MD, 1986) |
| "Four patients with disseminated histoplasmosis, two of whom had late relapses after previous therapy with amphotericin B, were treated with ketoconazole 200 to 400 mg daily for 1 year." | 3.66 | Progressive disseminated histoplasmosis; favorable response to ketoconazole. ( Alford, RH; Gregory, DW; Hawkins, SS, 1981) |
| "ketoconazole (n = 20) in dogs with Cushing's disease was assigned for a period of 180 d." | 2.72 | Retinoic acid as a novel medical therapy for Cushing's disease in dogs. ( Arzt, E; Castillo, V; Giacomini, D; Grossman, AB; Holsboer, F; Labeur, M; Páez-Pereda, M; Stalla, GK; Stalla, J; Theodoropoulou, M, 2006) |
| " However, no serious side effect were noted in all of the patients during treatment." | 2.67 | The efficacy and safety of ketoconazole in visceral leishmaniasis. ( Gachihi, GS; Kirigi, G; Mbugua, J; Nyakundi, PM; Rashid, JR; Wasunna, KM, 1994) |
| "American trypanosomiasis, or Chagas' disease, is caused by Trypanosoma cruzi and affects around 15 million people throughout the American continent." | 1.38 | In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole. ( Dias Filho, BP; Kaneshima, EN; Nakamura, CV; Sarragiotto, MH; Silva, SO; Tonin, LT; Ueda-Nakamura, T; Valdez, RH; Yamada-Ogatta, SF; Yamauchi, LM, 2012) |
| "Conventional methods to forecast CYP3A-mediated drug-drug interactions have not employed stochastic approaches that integrate pharmacokinetic (PK) variability and relevant covariates to predict inhibition in terms of probability and uncertainty." | 1.33 | Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. ( Chien, JY; Ernest, CS; Gorski, JC; Hall, SD; Lucksiri, A; Wrighton, SA, 2006) |
| "05), increasing absolute bioavailability from 0." | 1.31 | In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ( Cotreau, MM; Granda, BW; Greenblatt, DJ; Harmatz, JS; Kotegawa, T; Laurijssens, BE; Perloff, MD; Venkatakrishnan, K; Von Moltke, LL; Warrington, JS, 2002) |
| " For the current studies, male rats were dosed for 15 days via oral gavage and euthanized on the morning of test day 15." | 1.31 | Evaluation of a 15-day screening assay using intact male rats for identifying steroid biosynthesis inhibitors and thyroid modulators. ( Frame, SR; Ladics, GS; O'Connor, JC, 2002) |
| " Recently, this assay was evaluated by several laboratories using a variety of dosing schemes." | 1.31 | Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats. ( Carney, EW; Crissman, JW; Marty, MS, 2001) |
| "Clotrimazole treatment, in contrast to phenobarbital treatment, also caused a large induction of l-naphthol glucuronosyltransferase in females." | 1.27 | Induction of hepatic oxidative and conjugative drug metabolism in the hamster by N-substituted imidazoles. ( Franklin, MR; Ritter, JK, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valdez, RH | 1 |
| Tonin, LT | 1 |
| Ueda-Nakamura, T | 1 |
| Silva, SO | 1 |
| Dias Filho, BP | 1 |
| Kaneshima, EN | 1 |
| Yamada-Ogatta, SF | 1 |
| Yamauchi, LM | 1 |
| Sarragiotto, MH | 1 |
| Nakamura, CV | 1 |
| Kotegawa, T | 1 |
| Laurijssens, BE | 1 |
| Von Moltke, LL | 1 |
| Cotreau, MM | 1 |
| Perloff, MD | 1 |
| Venkatakrishnan, K | 1 |
| Warrington, JS | 1 |
| Granda, BW | 1 |
| Harmatz, JS | 1 |
| Greenblatt, DJ | 1 |
| O'Connor, JC | 1 |
| Frame, SR | 1 |
| Ladics, GS | 1 |
| Caksen, H | 1 |
| Tutuş, A | 1 |
| Kurtoğlu, S | 1 |
| Oztürk, F | 1 |
| Okumuş, Y | 1 |
| Coksevim, B | 1 |
| Chien, JY | 1 |
| Lucksiri, A | 1 |
| Ernest, CS | 1 |
| Gorski, JC | 1 |
| Wrighton, SA | 1 |
| Hall, SD | 1 |
| Castillo, V | 1 |
| Giacomini, D | 1 |
| Páez-Pereda, M | 1 |
| Stalla, J | 1 |
| Labeur, M | 1 |
| Theodoropoulou, M | 1 |
| Holsboer, F | 1 |
| Grossman, AB | 1 |
| Stalla, GK | 1 |
| Arzt, E | 1 |
| Hawkins, SS | 1 |
| Gregory, DW | 1 |
| Alford, RH | 1 |
| Rashid, JR | 1 |
| Wasunna, KM | 1 |
| Gachihi, GS | 1 |
| Nyakundi, PM | 1 |
| Mbugua, J | 1 |
| Kirigi, G | 1 |
| Laing, RB | 1 |
| Brettle, RP | 1 |
| Leen, CL | 1 |
| Cohen, H | 1 |
| Benjamin, J | 1 |
| Kaplan, Z | 1 |
| Kotler, M | 1 |
| Marty, MS | 1 |
| Crissman, JW | 1 |
| Carney, EW | 1 |
| Bonhomme-Faivre, L | 1 |
| Forestier, F | 1 |
| Auchère, D | 1 |
| Soursac, M | 1 |
| Orbach-Arbouys, S | 1 |
| Farinotti, R | 1 |
| Pakuts, AP | 1 |
| Parks, RJ | 1 |
| Paul, CJ | 1 |
| Bujaki, SJ | 1 |
| Mueller, RW | 1 |
| Ritter, JK | 1 |
| Franklin, MR | 1 |
| Willard, MD | 1 |
| Nachreiner, RF | 1 |
| Howard, VC | 1 |
| Fooshee, SK | 1 |
2 trials available for ketoconazole and Body Weight
| Article | Year |
|---|---|
Retinoic acid as a novel medical therapy for Cushing's disease in dogs.
Topics: Adenoma; Adrenocorticotropic Hormone; alpha-MSH; Animals; Body Weight; Creatinine; Dog Diseases; Dog | 2006 |
The efficacy and safety of ketoconazole in visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Body Weight; Child; Female; Hemoglobins; Humans; Ketoconazo | 1994 |
13 other studies available for ketoconazole and Body Weight
| Article | Year |
|---|---|
In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.
Topics: Amphotericin B; Animals; Body Weight; Carbolines; Cell Count; Cell Line; Chagas Disease; Drug Combin | 2012 |
In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
Topics: Algorithms; Animals; Anti-Anxiety Agents; Antifungal Agents; Biotransformation; Body Weight; Cytochr | 2002 |
Evaluation of a 15-day screening assay using intact male rats for identifying steroid biosynthesis inhibitors and thyroid modulators.
Topics: Androgens; Animals; Antibody Formation; Antithyroid Agents; Aromatase Inhibitors; Body Weight; Drug | 2002 |
Low dose ketoconazole therapy and thyroid functions in rats.
Topics: Animals; Antifungal Agents; Body Weight; Ketoconazole; Organ Size; Rats; Thyroid Gland; Thyrotropin; | 2002 |
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Topics: Age Factors; Body Weight; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibi | 2006 |
Progressive disseminated histoplasmosis; favorable response to ketoconazole.
Topics: Alkaline Phosphatase; Antifungal Agents; Body Weight; Dose-Response Relationship, Drug; Histoplasmos | 1981 |
Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Body Weight; Candidiasis; CD4 Lymphocyte C | 1998 |
Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model.
Topics: Animals; Anxiety; Body Weight; Disease Models, Animal; Endocrine Glands; Ketoconazole; Male; Psychom | 2000 |
Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats.
Topics: Animals; Body Weight; Dihydrotestosterone; Fadrozole; Finasteride; Genitalia, Male; Hormone Antagoni | 2001 |
Chronic administration of verapamil, ketoconazole and carbamazepine: impact on immunological parameters.
Topics: Animals; Anticonvulsants; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2002 |
Ketoconazole-induced hepatic lysosomal phospholipidosis: the effect of concurrent barbiturate treatment.
Topics: Animals; Barbiturates; Body Weight; In Vitro Techniques; Ketoconazole; Liver; Lysosomes; Mice; Micro | 1990 |
Induction of hepatic oxidative and conjugative drug metabolism in the hamster by N-substituted imidazoles.
Topics: Animals; Body Weight; Clotrimazole; Cricetinae; Cytochrome P-450 Enzyme System; Female; Glucuronates | 1987 |
Effect of long-term administration of ketoconazole in cats.
Topics: Alkaline Phosphatase; Animals; Body Weight; Calcium; Cats; Cholesterol; Hair; Hydrocortisone; Ketoco | 1986 |